高级检索
当前位置: 首页 > 详情页

Clinical significance of urine prostatic exosomal protein in the diagnosis of prostate cancer

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China [3]Department of Urology, Tong Ren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, People’sRepublic of China [4]Onco Biomedical Technology (Suzhou) Co., Ltd. Taicang, Jiangsu, People’s Republic of China.
出处:
ISSN:

关键词: Prostate cancer prostatic exosomal protein inflammation prostatitis

摘要:
PSA may be elevated in non-malignant conditions such as prostatitis and leads to unnecessary prostate needle biopsy. Urine prostatic exosomal protein (PSEP) has been proved to be a promising biomarker of prostatic inflammation. The aim of this study is to determine the relationships between PSEP and the diagnosis of prostate cancer (PCa), and their association with histologic prostatic inflammation. Prostate needle biopsies from 674 patients were evaluated for the presence of histological inflammation and PCa. The urine PSEP levels were measured using an enzyme-linked immunosorbent assay kit. 286 cases were diagnosed as PCa and prostatic inflammation was observed in 33.7% of the biopsies. The presence of histological inflammation was significantly associated with a lower PCa risk (P < 0.001). The urine PSEP levels was significantly lower in PCa patients compared to the controls (P = 0.003). When subanalyzed by PSA levels, the difference was more evident in cases with PSA 4-10 ng/ml (P = 0.039). The urine PSEP levels was correlated with histological inflammation on prostate needle biopsy (P = 0.018, r = 0.12). Urine PSEP examination may be helpful to eliminate false positive PSA levels due to prostatic inflammation and reduce unnecessary prostate needle biopsy in cases with PSA grey zone.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2017]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China [*1]Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong’an Road, Shanghai 200032, People’s Republic of China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21166 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)